aniracetam has been researched along with Supranuclear Palsy, Progressive in 1 studies
Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagasaka, T | 1 |
| Togashi, S | 1 |
| Amino, A | 1 |
| Nitta, K | 1 |
| Shindo, K | 1 |
| Shiozawa, Z | 1 |
1 other study available for aniracetam and Supranuclear Palsy, Progressive
| Article | Year |
|---|---|
Aniracetam for treatment of patients with progressive supranuclear palsy.
Topics: Aged; Dystonia; Electroencephalography; Eye Movements; Female; Gait; Humans; Male; Pyrrolidinones; S | 1997 |